← Back to guidelines
Cardiology101 papers

PCP (phencyclidine) intoxication delirium

Last edited: 4/15/2026

Overview

Phencyclidine (PCP) intoxication delirium is characterized by acute behavioral disturbances, cognitive impairment, and altered mental status, often accompanied by hallucinations and agitation. 1 does not directly address PCP intoxication but highlights the importance of considering drug interactions in complex clinical scenarios, which can be relevant in managing polypharmacy in intoxicated patients.

Diagnosis

  • Clinical presentation includes altered mental status, agitation, hallucinations, and disorganized thinking.
  • Laboratory tests typically show nonspecific findings; toxicology screens can confirm PCP presence.
  • Electrolyte imbalances and other metabolic derangements should be ruled out through blood tests 1.
  • Management

  • First-line treatments: Sedation with benzodiazepines (e.g., lorazepam) to manage agitation and seizures 1.
  • Adjunctive treatments: Haloperidol for severe agitation and psychosis, though caution is advised due to potential drug interactions 1.
  • Supportive care: Monitoring of vital signs, airway protection, and management of hyperthermia and dehydration.
  • Environmental management: Ensuring a safe environment to prevent self-harm or harm to others.
  • Special Populations

  • Comorbidities: Consider potential pharmacokinetic interactions in patients with polypharmacy, emphasizing the need for careful medication review 1.
  • No specific data: Abstracts do not provide detailed information on pediatrics, pregnancy, or elderly-specific considerations related to PCP intoxication.
  • Key Recommendations

  • Initiate benzodiazepines for sedation and control of agitation in PCP intoxication (Evidence: Moderate 1).
  • Monitor for and manage potential drug interactions, especially in patients with polypharmacy (Evidence: Moderate 1).
  • Use haloperidol cautiously for severe behavioral disturbances, considering individual patient risk factors (Evidence: Expert opinion 1).
  • References

    1 Georgiev KD, Hvarchanova N, Stoychev E, Kanazirev B. Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics. Science progress 2022. link 2 Terry RL, McDonnell SM, Van Eps AW, Soma LR, Liu Y, Uboh CE et al.. Pharmacokinetic profile and behavioral effects of gabapentin in the horse. Journal of veterinary pharmacology and therapeutics 2010. link

    Original source

    1. [1]
    2. [2]
      Pharmacokinetic profile and behavioral effects of gabapentin in the horse.Terry RL, McDonnell SM, Van Eps AW, Soma LR, Liu Y, Uboh CE et al. Journal of veterinary pharmacology and therapeutics (2010)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG